NCT04890613View on ClinicalTrials.gov

Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

PHASE1RecruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

September 8, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Advanced Solid Tumor
Interventions
DRUG

CX-5461

150 mg sterile lyophilized powder containing 1% sucrose

Trial Locations (8)

10065

WITHDRAWN

Memorial Sloan-Kettering Cancer Center, New York

15232

RECRUITING

UPMC Hillman Cancer Center, Pittsburgh

43202

RECRUITING

Ohio State University-James Cancer Hospital and Solove Research Institute, Columbus

90404

RECRUITING

University of California, Los Angeles, Santa Monica

33612-9497

RECRUITING

H. Lee Moffitt Cancer Center and Research Institute Hospital, Tampa

02215

RECRUITING

Dana Farber Cancer Institute, Boston

M5G 1X6

RECRUITING

Princess Margaret Cancer Centre, Toronto

H2X 0C2

RECRUITING

Centre hospitalier de l'Université de Montréal (CHUM), Montreal

All Listed Sponsors
lead

Senhwa Biosciences, Inc.

INDUSTRY

NCT04890613 - Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation | Biotech Hunter | Biotech Hunter